17,105 Labcorp Holdings Inc. $LH Shares Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. increased its holdings in Labcorp Holdings Inc. (NYSE:LH) by 355.2% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,921 shares of the medical research company’s stock after buying an additional 17,105 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Labcorp were worth $6,754,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in LH. Allied Private Wealth LLC acquired a new stake in shares of Labcorp in the second quarter valued at approximately $33,000. Cedar Mountain Advisors LLC increased its stake in Labcorp by 786.7% in the first quarter. Cedar Mountain Advisors LLC now owns 133 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 118 shares during the last quarter. Jones Financial Companies Lllp purchased a new position in shares of Labcorp during the 2nd quarter worth about $58,000. Ancora Advisors LLC purchased a new position in Labcorp during the second quarter worth approximately $67,000. Finally, Eastern Bank boosted its holdings in Labcorp by 1,740.0% in the second quarter. Eastern Bank now owns 276 shares of the medical research company’s stock valued at $77,000 after acquiring an additional 261 shares during the last quarter. 95.94% of the stock is owned by institutional investors and hedge funds.

Labcorp Stock Performance

Shares of LH opened at $329.10 on Friday. Labcorp Holdings Inc. has a 1 year low of $244.52 and a 1 year high of $341.80. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.53 and a current ratio of 1.80. The company has a market cap of $26.69 billion, a price-to-earnings ratio of 27.22, a price-to-earnings-growth ratio of 1.88 and a beta of 0.87. The firm has a fifty day moving average of $320.94 and a 200-day moving average of $290.99.

Labcorp (NYSE:LH) last released its quarterly earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, beating analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. The company had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.71 billion. During the same quarter in the previous year, the company posted $4.35 earnings per share. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. As a group, equities analysts anticipate that Labcorp Holdings Inc. will post 18.32 earnings per share for the current year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Tuesday, November 24th will be issued a $0.72 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. Labcorp’s dividend payout ratio (DPR) is 23.82%.

Insider Activity

In other news, EVP Amy B. Summy sold 924 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total transaction of $283,427.76. Following the completion of the transaction, the executive vice president owned 6,956 shares in the company, valued at approximately $2,133,683.44. This trade represents a 11.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Adam H. Schechter sold 4,669 shares of Labcorp stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the completion of the transaction, the chief executive officer directly owned 102,565 shares in the company, valued at $32,858,749.05. This represents a 4.35% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 8,593 shares of company stock worth $2,733,295. 0.84% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on LH shares. Mizuho set a $355.00 price objective on shares of Labcorp in a research report on Monday, August 10th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. JPMorgan Chase & Co. lifted their price target on shares of Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. Robert W. Baird set a $352.00 price target on shares of Labcorp in a report on Friday, July 31st. Finally, Truist Financial increased their price objective on shares of Labcorp from $350.00 to $365.00 and gave the company a “buy” rating in a research note on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Labcorp has a consensus rating of “Moderate Buy” and an average target price of $337.73.

Labcorp Profile

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.